Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial

Journal of Clinical Oncology

Volumn 31, Issue 7, 2013, Pages 903-909

  Demeestere, Isabelle ^a   Brice, Pauline ^f   Peccatori, Fedro A ⁱ   Kentos, Alain ^b   Gaillard, Isabelle ^g   Zachee, Pierre ^e   Casasnovas, Rene Olivier ^h   Neste, Eric Van Den ^c   Dechene, Julie ^a   Maertelaer, Vivianne De ^a   Bron, Dominique ^d   Englert, Yvon ^a,b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c Department of Radiology   (Belgium)

^d JULES BORDET INSTITUTE   (Belgium)

^e Stuivenberg General Hospital   (Belgium)

^f SAINT LOUIS HOSPITAL   (France)

^g Service d'Immunologie Clinique   (France)

^h DIJON UNIVERSITY HOSPITAL   (France)

ⁱ EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; MUELLERIAN INHIBITING FACTOR; NORETHISTERONE; NORETHISTERONE ACETATE; TRIPTORELIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; METRORRHAGIA; NONHODGKIN LYMPHOMA; OVARY FUNCTION; OVARY INSUFFICIENCY; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HODGKIN DISEASE; HUMANS; LUTEOLYTIC AGENTS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; NORETHINDRONE; PREMENOPAUSE; PRIMARY OVARIAN INSUFFICIENCY; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE; TRIPTORELIN PAMOATE;

EID: 84875696905     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.8185     Document Type: Article

References (36)

1. Verdecchia A, Francisci S, Brenner H, et al: Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8:784- 796, 2007.
2. Brenner H, Coebergh JW, Parkin DM, et al: Up-to-date monitoring of childhood cancer long-term survival in Europe: Leukaemias and lymphomas. Ann Oncol 18:1569-1577, 2007.
3. Brougham MF, Wallace WH: Subfertility in children and young people treated for solid and haematological malignancies. Br J Haematol 131: 143-155, 2005.
4. Lee SJ, Schover LR, Partridge AH, et al: American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24:2917-2931, 2006.
5. Demeestere I, Simon P, Emiliani S, et al: Orthotopic and heterotopic ovarian tissue transplantation. Hum Reprod Update 15:649-665, 2009.
6. Demeestere I, Simon P, Emiliani S, et al: Fertility preservation: Successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin's disease. Oncologist 12:1437-1442, 2007.
7. Blumenfeld Z: How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 12:1044-1054, 2007.
8. Woodruff TK: Preserving fertility during cancer treatment. Nat Med 15:1124-1125, 2009.
9. Imai A, Sugiyama M, Furui T, et al: Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest 63:102-106, 2007.
10. Ataya K, Rao LV, Lawrence E, et al: Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide- induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 52:365-372, 1995.
11. Beck-Fruchter R, Weiss A, Shalev E: GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: A review of the clinical data. Hum Reprod Update 14:553-561, 2008.
12. Peccatori F, Demeestere I: GnRH analogue for chemotherapy-induced ovarian damage: Too early to say? Fertil Steril 92:e33, 2009.
13. Levine J, Canada A, Stern CJ: Fertility preservation in adolescents and young adults with cancer. J Clin Oncol 28:4831-4841, 2010.
14. Rugo HS, Rosen MP: Reducing the long-term effects of chemotherapy in young women with early-stage breast cancer. JAMA 306:312-314, 2011.
15. Munster PN, Moore AP, Ismail-Khan R, et al: Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 30:533-538, 2012.
16. Gerber B, von Minckwitz G, Stehle H, et al: Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: The GBG 37 ZORO study. J Clin Oncol 29:2334-2341, 2011.
17. Del Mastro L, Boni L, Michelotti A, et al: Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: A randomized trial. JAMA 306:269-276, 2011.
18. Hodgson DC, Pintilie M, Gitterman L, et al: Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 25:11-15, 2007.
19. Tsepelidis S, Devreker F, Demeestere I, et al: Stable serum levels of anti-Müllerian hormone during the menstrual cycle: A prospective study in normo-ovulatory women. Hum Reprod 22:1837- 1840, 2007.
20. Behringer K, Breuer K, Reineke T, et al: Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 23:7555-7564, 2005.
21. Abdalla H, Thum MY: An elevated basal FSH reflects a quantitative rather than qualitative decline of the ovarian reserve. Hum Reprod 19:893-898, 2004.
22. Pal L, Zhang K, Zeitlian G, et al: Characterizing the reproductive hormone milieu in infertile women with diminished ovarian reserve. Fertil Steril 93: 1074-1079, 2010.
23. Decanter C, Morschhauser F, Pigny P, et al: Anti-Mullerian hormone follow-up in young women treated by chemotherapy for lymphoma: Preliminary results. Reprod Biomed Online 20:280-285, 2009.
24. Meirow D, Rabinovici J, Katz D, et al: Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depomedroxyprogesterone acetate. Cancer 107:1634- 1641, 2006.
25. Blumenfeld Z, Avivi I, Linn S, et al: Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 11:1620-1626, 1996.
26. Pereyra Pacheco B, Méndez Ribas JM, Milone G, et al: Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: A preliminary report. Gynecol Oncol 81:391-397, 2001.
27. Huser M, Crha I, Ventruba P, et al: Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. Hum Reprod 23:863-868, 2008.
28. Castelo-Branco C, Nomdedeu B, Camus A, et al: Use of gonadotropin- releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertil Steril 87:702-705, 2007.
29. Blumenfeld Z, Avivi I, Eckman A, et al: Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril 89:166-173, 2008.
30. Del Mastro L, Catzeddu T, Boni L, et al: Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 17:74-78, 2006.
31. Recchia F, Saggio G, Amiconi G, et al: Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 106:514-523, 2006.
32. Franke HR, Smit WM, Vermes I: Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy. Gynecol Endocrinol 20: 274-278, 2005.
33. Waxman JH, Ahmed R, Smith D, et al: Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 19:159-162, 1987.
34. Behringer K, Wildt L, Mueller H, et al: No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma: Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol 21:2052-2060, 2010.
35. Badawy A, Elnashar A, El-Ashry M, et al: Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: Prospective randomized study. Fertil Steril 91:694- 697, 2009.
36. Ismail-Khan R, Minton S, Cox C, et al: Preservation of ovarian function in young woman treated with neoadjuvant chemotherapy for breast cancer: A randomized trial using the GnRh agonist (triptorelin) during chemotherapy. J Clin Oncol 28:12s, 2008 (suppl 15; abstr 524).